Loading...
Pulse Biosciences posted a GAAP net loss of $19.2M in Q2 2025, with no revenue reported and increased spending in R&D and G&A. The company ended the quarter with over $106M in cash.
No product revenue reported for the quarter.
GAAP net loss increased to $19.2M from $11.4M in Q2 2024.
Cash and cash equivalents stood at $106.3M at quarter-end.
Stock-based compensation rose to $5.2M from $2.1M last year.
Pulse Biosciences did not provide specific financial guidance but outlined plans to continue IDE studies and expand pilot programs.
Analyze how earnings announcements historically affect stock price performance